Consensus Perrigo Company plc

Equities

PRGO

IE00BGH1M568

Market Closed - Nyse 04:00:02 2024-03-27 pm EDT 5-day change 1st Jan Change
31.46 USD +2.14% Intraday chart for Perrigo Company plc +0.51% -2.24%

Evolution of the average Target Price on Perrigo Company plc

Price target over the last 5 years

History of analyst recommendation changes

4eb83f38132c613a4597b738707.mrM_HAd3hi5qLW4pQGIdtMG--DwbdVenShBc0C-mJUo.-PVoUnQC1VcyXw9ICAlVgrCKiVBNWBj4PlETt2jkaR7w_nNFRTrXX1JiKw~387e3e47896f1c2991cf422ee52b47f6
JPMorgan Cuts Price Target on Perrigo to $41 From $48, Maintains Overweight Rating MT
Canaccord Genuity Starts Perrigo at Buy With $49 Price Target MT
Raymond James Adjusts Perrigo Price Target to $43 From $42, Maintains Outperform Rating MT
Raymond James Adjusts Price Target on Perrigo Company to $42 From $48, Maintains Outperform Rating MT
Argus Upgrades Perrigo to Buy From Hold; Price Target is $46 MT
Wells Fargo Raises Perrigo to Overweight From Equalweight, Price Target to $54 From $48 MT
PERRIGO REPORTS FIRST QUARTER FISCAL YEAR 2022 FINANCIAL RESULTS FROM CONTINUING OPERATIONS, RAISES GUIDANCE PR
Raymond James Adjusts Perrigo's Price Target to $48 from $55, Keeps Outperform Rating MT
Raymond James Adjusts Price Target on Perrigo to $55 From $59, Maintains Outperform Rating MT
PERRIGO : Raymond James Upgrades Perrigo to Outperform from Market Perform, Sets $59 Price Target MT
PERRIGO : Jefferies Upgrades Perrigo to Buy from Hold, Adjusts PT to $63 from $45 MT
PERRIGO : Jefferies Upgrades Perrigo to Buy from Hold, Adjusts Price Target to $63 from $45 MT
PERRIGO : RBC Cuts Price Target on Perrigo to $48 From $51 After Q2 Results Miss Expectations; Sector Perform Rating Maintained MT
Health Care Slips As Traders Rotate Into Rate-Sensitive Sectors -- Health Care Roundup DJ
PERRIGO : Morgan Stanley Adjusts Perrigo Company PT to $45 From $53, Maintains Equal Weight Rating MT
PERRIGO : RBC Capital Adjusts Perrigo's Price Target to $51 From $49, Maintains Sector Perform Rating MT
PERRIGO : RBC Capital Downgrades Perrigo Company to Sector Perform From Outperform, Adjusts PT to $49 From $59 MT
Perrigo and Catalent Announce FDA Approval of Perrigo's AB-rated Generic Version of ProAir HFA CI
Perrigo Company plc Announces the Relaunch of the AB Rated Generic Version of Transderm Scop 1.5 Mg CI
Perrigo Company plc Announces FDA Final Approval and Launch of the AB-Rated Generic Version of Metrogel-Vaginal Gel CI
Perrigo Announces FDA Final Approval for AB Rated Generic Version of Voltaren® Gel 1% CI
Perrigo Announces FDA Final Approval for its AB Rated Generic Version of Zovirax® Cream 5% CI
Perrigo Announces the Launch of an AB Rated Generic Version of Topicort® Topical Spray 0.25% CI
Perrigo Company plc Launches Its AB Rated Generic Version of Solaraze® Gel 3% CI
Perrigo Company plc Announces the Launch of An AB Rated Generic Version of Androgel® Topical Gel, 1.62% CI
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
31.46 USD
Average target price
38.75 USD
Spread / Average Target
+23.17%
High Price Target
42 USD
Spread / Highest target
+33.50%
Low Price Target
35 USD
Spread / Lowest Target
+11.25%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Perrigo Company plc

JPMorgan Chase
Canaccord Genuity
Raymond James
Argus
Wells Fargo Securities
Jefferies & Co.
RBC Capital Markets
Morgan Stanley
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings